Body

Combination therapy reduced HER2-positive breast cancers

SAN ANTONIO — A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT.

Reporters who cannot attend in person can participate using the following call-in information:

Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer

SAN ANTONIO — Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer

SAN ANTONIO — The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.

Details of these study results were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

Early study analysis suggests exemestane reduces breast density in high risk postmenopausal women

San Antonio, Tex. -- A drug that shows promise for preventing breast cancer in postmenopausal women with an increased risk of developing the disease, appears to reduce mammographic breast density in the same group of women. Having dense breast tissue on mammogram is believed to be one of the strongest predictors of breast cancer. The preliminary analysis from the small, phase II study was presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in Texas.

Gene knockout shows potential for diabetes-related heart failure

Silencing the TLR4 gene can stop the process which may lead to cardiovascular disease in diabetic patients. Researchers writing in BioMed Central's open access Journal of Translational Medicine carried out a series of in vitro tests which demonstrated that TLR4 plays a critical role in hyperglycaemic cardiac apoptosis, and that silencing the gene using specific small interfering RNA (siRNA) can prevent it.

Cutting dietary phosphate doesn't save dialysis patients' lives

Doctors often ask kidney disease patients on dialysis to limit the amount of phosphate they consume in their diets, but this does not help prolong their lives, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The results even suggest that prescribing low phosphate diets may increase dialysis patients' risk of premature death.

Cholera strain in Haiti matches bacteria from south Asia

BOSTON, Mass. (December 9, 2010)—A team of researchers from Harvard Medical School, Brigham and Women's Hospital, and Massachusetts General Hospital, with others from the United States and Haiti, has determined that the strain of cholera erupting in Haiti matches bacterial samples from South Asia and not those from Latin America. The scientists conclude that the cholera bacterial strain introduced into Haiti probably came from an infected human, contaminated food or other item from outside of Latin America.

Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen

Menlo Park, Calif. – December 9, 2010 – Scientists from Pacific Biosciences of California, Inc. (NASDAQ: PACB) and Harvard Medical School have successfully employed single molecule, real-time (SMRT™) DNA sequencing technology to rapidly characterize the pathogen responsible for the recent deadly cholera epidemic in Haiti. Published Thursday in the New England Journal of Medicine, the results provide the first whole genome sequence analysis and most detailed genetic profile to date of the Haitian Vibrio cholerae outbreak strain.

Gene that causes some cases of familial ALS discovered

Using a new gene sequencing method, a team of researchers led by scientists from Johns Hopkins and the National Institutes of Health has discovered a gene that appears to cause some instances of familial amyotrophic lateral sclerosis (ALS). The finding could lead to novel ways to treat the more common form of this fatal neurodegenerative disease, which kills the vast majority of the nearly 6,000 Americans diagnosed with ALS every year.

A new kind of blast-resistant glass

A new kind of blast-resistant glass

Whether in a hurricane, tornado, or bomb attack, a leading cause of injury and death is often fast-flying shards of glass. Explosions and high winds can cause windows in buildings to shatter-spewing jagged pieces of glass in every direction.

A Pentagon report on the 1996 Khobar Towers bombing in Saudi Arabia, for example, noted:

Official food allergy treatment guidelines released

A collaborative, government-led effort to guide and standardize diagnosis, treatment and management of food allergies has resulted in the release of an official set of recommendations for physicians.

Buprenorphine is better than methadone for opioid dependence in pregnant women, study shows

Using buprenorphine instead of methadone — the current standard of care — to treat opioid-dependent pregnant women may result in healthier babies, suggests new findings from an international team led by Johns Hopkins researchers and published in the Dec. 9 issue of the New England Journal of Medicine.

There's a new 'officer' in the infection control army

Johns Hopkins scientists have identified a previously unrecognized step in the activation of infection-fighting white blood cells, the main immunity troops in the body's war on bacteria, viruses and foreign proteins.

"It's as if we knew many of the generals, colonels and majors and now we have discovered a new officer that helps the troops carry out the right battle plan," says Joel Pomerantz, Ph.D., an assistant professor of Biological Chemistry in the Institute for Basic Biomedical Sciences and member of the Institute for Cell Engineering at Johns Hopkins.

Supercomputing research opens doors for drug discovery

OAK RIDGE, Tenn., Dec. 9, 2010 -- A quicker and cheaper technique to scan molecular databases developed at the Department of Energy's Oak Ridge National Laboratory could put scientists on the fast track to developing new drug treatments.

A team led by Jerome Baudry of the University of Tennessee-ORNL Center for Molecular Biophysics adapted a widely used existing software to allow supercomputers such as ORNL's Jaguar to sift through immense molecular databases and pinpoint chemical compounds as potential drug candidates.

Researcher develops accurate method for detecting dangerous fluoride

Researcher develops accurate method for detecting dangerous fluoride